Lead Product(s): Vafidemstat
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Spanish Ministry of Science and Innovation
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding June 15, 2020
Oryzon's project “VENCER: Vafidemstat Efficacy in the treatment against Schizophrenia and other related pathologies has been approved for funding by the Spanish Ministry of Science and Innovation under the 2019 call of the governmental R&D “RETOS-COLABORACION” program.